Ticker: LIVN

LivaNova PLC (NASDAQ: LIVN) has recently released its quarterly report for the period ending March 31, 2025. The company, which specializes in medical technologies, has faced both challenges and opportunities as it navigates a complex operating environment. Key Highlights from the Income Statemen...

LivaNova PLC (NASDAQ: LIVN) surpassed Q3 earnings expectations with adjusted EPS of $0.90 and revenue of $318.1 million, boosting its 2024 outlook. With strong gains in cardiopulmonary and neuromodulation segments, traders should watch this upward trajectory closely.